
Please try another search
(Reuters) -The U.S. Department of Justice has asked for more details on CVS Health Corp (NYSE:CVS)'s proposed $8 billion deal to buy Signify Health, in a possible indication that the companies face a longer deal investigation rather than a quick approval.
The deal, announced last month, was expected to face a tough antitrust review even though the two companies do not compete directly in any market, according to experts.
Large mergers and acquisitions have come under intense antitrust scrutiny, and lowering healthcare costs has been an important strategic mission for the Biden Administration.
UnitedHealth Group (NYSE:UNH) earlier this month completed its acquisition of Change Healthcare (NASDAQ:CHNG), after over a year of antitrust scrutiny.
Acquiring Signify Health will enable CVS, which operates a pharmacy chain, a health insurance business and offers pharmacy benefit management services, to provide further care management for at-home patients.
The deal is expected to close in the first half of 2023, CVS said in a filing on Thursday.
Signify offers technology and analytics to help with at-home care for patients. It has said its services can help identify potential health risks and gaps in care.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.